VCG
ADCT icon

Vantage Consulting Group’s ADC Therapeutics ADCT Stock Holding History

Vantage Consulting Group’s Portfolio ADCT Stock Details ADCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		$2.41M Hold
682,998
– – 12.23% 2
2025
Q3 		$2.73M Hold
682,998
– – 24.36% 2
2025
Q2 		$1.83M Sell
682,998
-167,739
-20% -$353K 31.92% 2
2025
Q1 		$1.2M Hold
850,737
– – 23.88% 3
2024
Q4 		$1.69M Hold
850,737
– – 16.14% 3
2024
Q3 		$2.68M Hold
850,737
– – 23.47% 3
2024
Q2 		$2.69M Hold
850,737
– – 2% 6
2024
Q1 		$3.82M Hold
850,737
– – 2.43% 4
2023
Q4 		$1.41M Hold
850,737
– – 0.95% 7
2023
Q3 		$763K Sell
850,737
-34,783
-4% -$46.3K 0.51% 7
2023
Q2 		$1.9M Sell
885,520
-300,695
-25% -$676K 1.1% 7
2023
Q1 		$2.31M Hold
1,186,215
– – 1.31% 6
2022
Q4 		$4.56M Hold
1,186,215
– – 2.69% 5
2022
Q3 		$5.72M Hold
1,186,215
– – 3.34% 4
2022
Q2 		$9.43M Sell
1,186,215
-493,934
-29% -$4.67M 5.29% 3
2022
Q1 		$24.7M Hold
1,680,149
– – 9.63% 3
2021
Q4 		$33.9M Hold
1,680,149
– – 9.12% 3
2021
Q3 		$45.6M Hold
1,680,149
– – 9.77% 3
2021
Q2 		$40.9M Hold
1,680,149
– – 7.12% 3
2021
Q1 		$41M Hold
1,680,149
– – 8.23% 2
2020
Q4 		$53.8M Buy
+1,680,149
New +$55.1M 4.38% 2

Other funds holding ADCT

RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Vantage Consulting Group's ADCT Position: Q4 2025 in Review

Vantage Consulting Group held its ADC Therapeutics (ADCT) position steady in Q4 2025 at 682,998 shares worth $2.41M. The position accounts for 12.23% of the portfolio, ranked #2.

Vantage Consulting Group first reported a position in ADCT in Q4 2020 and has held it in 21 quarters since. The position peaked at $53.8M in Q4 2020. 115 funds tracked by Wall St. Rank hold ADCT as of Q4 2025.

  • Vantage Consulting Group held 682,998 shares of ADC Therapeutics worth $2.41M as of Q4 2025.
  • Vantage Consulting Group left its ADC Therapeutics share count unchanged in Q4 2025.
  • ADC Therapeutics made up 12.23% of Vantage Consulting Group's portfolio in Q4 2025, its #2 holding.
  • Vantage Consulting Group first reported a position in ADC Therapeutics in Q4 2020 and has held it in 21 quarters since.
  • Vantage Consulting Group's ADC Therapeutics position peaked at $53.8M in Q4 2020.
  • 115 funds tracked by Wall St. Rank held ADC Therapeutics as of Q4 2025.

Based on Vantage Consulting Group's 13F filing for Q4 2025, filed 11 Feb 2026.